Syros Pharmaceuticals (SYRS)
(Real Time Quote from BATS)
$5.25 USD
+0.21 (4.17%)
Updated Apr 29, 2024 11:48 AM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SYRS 5.25 +0.21(4.17%)
Will SYRS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SYRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRS
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
SYRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why
Other News for SYRS
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
Syros jumps on FDA fast track tag for leukemia drug